• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病或糖耐量受损作为高剂量治疗和自体骨髓移植患者潜在的复杂因素。

Diabetes mellitus or an impaired glucose tolerance as a potential complicating factor in patients treated with high-dose therapy and autologous bone marrow transplantation.

作者信息

Schouten H C, Maragos D, Vose J, Armitage J O

机构信息

Department of Internal Medicine, University of Nebraska Medical Center, Omaha.

出版信息

Bone Marrow Transplant. 1990 Nov;6(5):333-5.

PMID:2291995
Abstract

We asked in a retrospective analysis whether patients with diabetes mellitus or impaired glucose tolerance are at increased risk for morbidity and mortality after high-dose therapy followed by an autologous bone marrow transplantation. Nine patients with diabetes mellitus (n = 7) or impaired glucose tolerance (n = 2) were identified who had been treated with high-dose therapy and autologous bone marrow transplant for lymphoid malignancies. At the start of the pretransplant conditioning all patients had a Karnofsky score of at least 80 and no clinically demonstrable organ dysfunction. One patient with diabetes mellitus type I (DM I) was transplanted without any complications. The patients with diabetes mellitus type II (DM II) or an impaired glucose tolerance had complications of life-threatening infections (in 6/8), acute renal insufficiency (in 3/8), liver abnormalities with elevated liver enzymes or liver failure (in 4/8) and congestive heart failure (in 1/8). Although the complications observed are not infrequent in the transplant setting, because of the good performance status before BMT and the absence of clinically demonstrable organ impairment before transplantation, it is our impression that the presence of diabetes mellitus or glucose intolerance might be an important co-factor in the morbidity of these patients.

摘要

我们在一项回顾性分析中探究,糖尿病或糖耐量受损患者在接受大剂量治疗后进行自体骨髓移植,其发病和死亡风险是否会增加。我们确定了9例患有糖尿病(n = 7)或糖耐量受损(n = 2)的患者,他们因淋巴系统恶性肿瘤接受了大剂量治疗和自体骨髓移植。在移植前预处理开始时,所有患者的卡氏评分至少为80分,且无临床可证实的器官功能障碍。1例I型糖尿病(DM I)患者移植过程无任何并发症。II型糖尿病(DM II)或糖耐量受损的患者出现了危及生命的感染并发症(6/8)、急性肾功能不全(3/8)、伴有肝酶升高的肝脏异常或肝衰竭(4/8)以及充血性心力衰竭(1/8)。尽管在移植过程中观察到的这些并发症并不罕见,但鉴于骨髓移植前患者的身体状况良好且移植前无临床可证实的器官损害,我们认为糖尿病或糖耐量不耐受的存在可能是这些患者发病的一个重要协同因素。

相似文献

1
Diabetes mellitus or an impaired glucose tolerance as a potential complicating factor in patients treated with high-dose therapy and autologous bone marrow transplantation.糖尿病或糖耐量受损作为高剂量治疗和自体骨髓移植患者潜在的复杂因素。
Bone Marrow Transplant. 1990 Nov;6(5):333-5.
2
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.异环磷酰胺、依托泊苷、阿糖胞苷和地塞米松作为挽救治疗,随后进行大剂量环磷酰胺、美法仑和依托泊苷联合自体外周血干细胞移植用于复发或难治性淋巴瘤。
Eur J Haematol. 2007 Feb;78(2):93-101. doi: 10.1111/j.1600-0609.2006.00796.x.
3
BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.淋巴瘤患者接受BEAM化疗后自体干细胞支持治疗:疗效、毒性及预后因素分析
Bone Marrow Transplant. 1997 Sep;20(6):451-8. doi: 10.1038/sj.bmt.1700913.
4
Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.高剂量环磷酰胺、依托泊苷和顺铂序贯自体骨髓或外周血干细胞移植治疗预后不良的霍奇金淋巴瘤或非霍奇金淋巴瘤的I/II期研究
Bone Marrow Transplant. 1993 Oct;12(4):337-45.
5
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.复发侵袭性淋巴瘤的治疗:含与不含高剂量治疗及干细胞救援的方案
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12.
6
Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.白消安、环磷酰胺和依托泊苷作为恶性淋巴瘤患者的大剂量预处理疗法及既往的剂量限制性放射治疗
Bone Marrow Transplant. 1998 Jun;21(12):1171-5. doi: 10.1038/sj.bmt.1701245.
7
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.对于高危或晚期血液系统恶性肿瘤患者,采用分次全身照射、依托泊苷和环磷酰胺治疗,随后进行异基因骨髓移植。
Biol Blood Marrow Transplant. 1997 Dec;3(6):324-30.
8
High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.采用BEAC方案的大剂量化疗及自体骨髓移植治疗中级别和免疫母细胞淋巴瘤:持久完全缓解,但方案相关毒性发生率高。
Bone Marrow Transplant. 1995 Apr;15(4):549-55.
9
Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation.大剂量依托泊苷及自体骨髓移植后的周围神经病变
Bone Marrow Transplant. 1994 Jan;13(1):77-9.
10
Delayed neutrophil recovery after BEAM chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection.
Bone Marrow Transplant. 1995 Feb;15(2):313-5.